SciSparc Ltd.

Snapshot

SciSparc is a clinical-stage cannabinoid drug developer with almost no revenue: $856K in FY2025, down 34.5% YoY, against a $12.2M net loss, meaning losses run over 14 times revenue.

What's Happening Right Now

• Thu 15th Oct '26 · Debt conversion: SciSparc struck an inducement deal to convert $2.02M of convertible note principal and interest into shares at $1.50, adding roughly 1.35 million new shares with no cash to the company, closing around Oct 16, 2026.
• Thu 15th Oct '26 · Strategic pivot: SciSparc announced a shift toward Agentic AI, cybersecurity, and finance technology, saying no transaction or revenue-generating deal has yet been identified while its core business remains clinical-stage cannabinoid drug development.
• Wed 30th Sep '26 · Going concern: A 6-K for the six months ended June 30, 2026 disclosed a $6.05M net loss on just $284K revenue, negative working capital of $1.4M, and explicit going-concern doubt with only $4.4M cash on hand.
• Thu 10th Sep '26 · Dilution filing: An F-3/A registered resale of up to 2.56 million shares tied to a $2.0M convertible note and warrants, against only 580,973 shares outstanding at the time, a potential 5x increase in share count.
• Thu 10th Sep '26 · Subsidiary financing: Subsidiary NeuroThera Labs closed a C$5.4M private placement, with SciSparc contributing C$2.7M for a stake it values at roughly C$30M, now holding about 44.6% of NeuroThera.
• Mon 31st Aug '26 · Registration: Registered 2.56M shares for sale on Form F-3.
• Thu 12th Feb '26 · Registration: Registered $50.00M of securities for sale on Form F-3.
• Thu 12th Feb '26 · Offering: Raised $1.80M in gross proceeds through a private placement (PIPE), with warrants over 406K shares and a $2.00M convertible note.